{"title":"Serum Interleukin 17 and Interleukin 33 in Vitiligo Egyptian Patients","authors":"Ibrahim ElGhareeb M, E. S, Fathi M, K. N, Gado M","doi":"10.26420/austinjdermatolog.2021.1093","DOIUrl":null,"url":null,"abstract":"Background: Vitiligo is an acquired depigmented disorder characterized by milky-white macules in the skin. Interleukin-17 has important role in autoimmune diseases development like vitiligo. Interleukin-33 is released after tissue damage or cell death. It may reflect recent disease activity. Aim: To measure serum levels of IL17 and IL-33 in vitiligo patients and to assess their relationship with disease activity. Methods: Levels of IL17 and IL-33 in serum samples taken from 21 healthy normal subjects and 21 vitiligo patients were measured by ELISA. All the patients were subjected to careful history taking , general examination and local examination to assess extent ,activity of vitiligo and VASI score. Results: IL17 and IL-33 serum levels were highly statistically significant increase in patients with vitiligo than the normal control subjects(p≤0.001). Their levels were related to disease activity and the extent of the disease. Interleukin 17 serum levels were positively correlated with IL-33 serum levels. Conclusion: Increased serum levels of IL-17 and IL-33 in vitiligo patients and their levels were related to disease activity and the extent of the disease indicating that IL-17 and IL-33 may play a role in the pathogenesis of vitiligo.","PeriodicalId":247251,"journal":{"name":"Austin Journal of Dermatology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Austin Journal of Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/austinjdermatolog.2021.1093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Vitiligo is an acquired depigmented disorder characterized by milky-white macules in the skin. Interleukin-17 has important role in autoimmune diseases development like vitiligo. Interleukin-33 is released after tissue damage or cell death. It may reflect recent disease activity. Aim: To measure serum levels of IL17 and IL-33 in vitiligo patients and to assess their relationship with disease activity. Methods: Levels of IL17 and IL-33 in serum samples taken from 21 healthy normal subjects and 21 vitiligo patients were measured by ELISA. All the patients were subjected to careful history taking , general examination and local examination to assess extent ,activity of vitiligo and VASI score. Results: IL17 and IL-33 serum levels were highly statistically significant increase in patients with vitiligo than the normal control subjects(p≤0.001). Their levels were related to disease activity and the extent of the disease. Interleukin 17 serum levels were positively correlated with IL-33 serum levels. Conclusion: Increased serum levels of IL-17 and IL-33 in vitiligo patients and their levels were related to disease activity and the extent of the disease indicating that IL-17 and IL-33 may play a role in the pathogenesis of vitiligo.